Treating haemophilia A with recombinant blood factors: A comparison

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 5, 2004, Pages 1061-1070

  Ananyeva, Natalya ^a   Khrenov, Alexey ^a   Darr, Fred ^b   Summers, Robert ^b   Sarafanov, Andrey ^a   Saenko, Evgueni ^a  

^a HOLLAND LABORATORY   (United States)

^b AMERICAN RED CROSS   (United States)

Author keywords

Blood borne pathogens; Efficacy; Factor VIII; FVIII concentrate consumption; Haemophilia A; Plasma derived; Recombinant; Safety; Unconstrained FVIII demand

Indexed keywords

BLOOD CLOTTING FACTOR 8; MANNOSE BINDING LECTIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ASSAY; BIOENGINEERING; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEMOPHILIA A; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW; SIDE EFFECT; STANDARDIZATION;

ANIMALS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FACTOR VIII; HEMOPHILIA A; HUMANS; MULTICENTER STUDIES; RECOMBINANT PROTEINS;

EID: 2542586370     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.5.1061     Document Type: Review

References (80)

1. ROBERTS HR, HOFFMAN M: Hemophilia A and Hemophilia B. In: Williams Hematology (6th edition) Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn V (Eds), McGraw-Hill, New York, USA (2001):1639-1657.
2. GITSCHIER J, WOOD WI, GORALKA TM et al.: Characterization of the human Factor VIII gene. Nature (1984) 312:326-330.
3. TOOLE JJ, KNOPF JL, WOZNEY JM et al: Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature (1984) 312:342-347.
4. WOOD WI, CAPON DJ, SIMONSEN CC et al.: Expression of active human Factor VIII from recombinant DNA clones. Nature (1984) 312:330-337.
5. LARSSON SA: Life expectancy of Swedish haemophiliacs, 1831-1980. Br. J. Haematol. (1985) 59:593-602.
6. RIZZA CR, SPOONER RJ, GIANGRANDE PL: Treatment of haemophilia in the United Kingdom 1981-1996. Haemophilia (2001) 7:349-359.
7. ROYAL S, SCHRAMM W, BERNTORP E et al.: Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia (2002) 8:44-50.
8. SOUCIE JM, NUSS R, EVATT B et al.: Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood (2000) 96:437-442.
9. GIANGRANDE PL: Treatment of hemophilia: recombinant factors only? Yes. J. Thromb. Haemost. (2003) 1:214-215.
10. MANNUCCI PM: Treatment of hemophilia: recombinant factors only? No. J. Thromb. Haemost. (2003) 1:216-217.
11. MANNUCCI PM: Hemophilia. treatment options in the twenty-first century. J. Thromb. Haemost. (2003) 1:1349-1355.
12. GIANGRANDE PL: Choice of replacement therapy for hemophilia - a rebuttal. J. Thromb. Haemost. (2003) 1:2698-2699.
13. LEE C: The use of recombinant Factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. Semin. Thromb. Hemost. (2002) 28:241-246.
14. LUSHER JM: First and second generation recombinant Factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin. Thromb. Hemost. (2002)
15. KRONER BL, ROSENBERG PS, ALEDORT LM, ALVORD WG, GOEDERT JJ: HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J. Acquir. Immune. Defic. Syndr. (1994) 7:279-286.
16. HOROWITZ B, LAZO A, GROSSBERG H et al.: Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang. (1998) 74(Suppl. 1):203-206.
17. HILFENHAUS J, NOWAK T: Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of Factor VIII concentrate. Vox Sang. (1994) 67(Suppl. 1):62-66.
18. DICHTELMULLER H, RUDNICK D, BREUER B et al.: Improvement of virus safety of a S/D-treated Factor VIII concentrate by additional dry heat treatment at 100 degrees C. Biologicals (1996) 24:125-130.
19. SOUCIE JM, ROBERTSON BH, BELL BP, MCCAUSTLAND KA, EVATT BL: Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion (1998) 38:573-579.
20. AZZI A, MORFINI M, MANNUCCI PM: The transfusion-associated transmission of parvovirus B19. Tansfus. Med Rev. (1999) 13:194-204.
21. GIANGRANDE PLF, TAYLOR S: Communicating risk: the example of vCJD. Proceedings of the World Federation of Haemophilia Global Forum on the Safety and Supply of Hemophilia Treatment Products (2002):37-39.
22. OLDENBURG J, BRACKMANN HH, SCHWAAB R: Fisk factors for inhibitor: development in hemophilia A. Haematologica (2000) 85:7-13.
23. LUSHER JM: Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials. Haematologica (2000) 85:2-5.
24. SCHARRER I, BRAY GL, NEUTZLING O: Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived Factor VIII concentrates. Haemophilia (1999) 5:145-154.
25. KREUZ W. ETTINGSHAUSEN CE, ZYSCHKA A et al.: Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin. Thromb. Hemost. (2002) 28:285-290.
26. SCHARRER I, EHRLICH HJ: Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant Factor VIII. Haemophilia (2001) 7:346-348.
27. BEHRMANN M, PASI J, SAINT-REMY JM, KOTITSCHKE R, KLOFT M: Von Willebrand factor modulates Factor VIII immunogenicity: comparative study of different Factor VIII concentrates in a haemophilia A mouse model. Thromb. Haemost. (2002) 88:221-229.
28. AUERSWALD G, SPRANGER T, BRACKMANN HH: The role of plasma-derived Factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica (2003) 88:EREP05.
29. RAUT S, HEATH AB, BARROWCLIFFE TW: A collaborative study to establish the 6th International Standard for Factor VIII concentrate. Thromb. Haemost. (2001) 85:1071-1078.
30. BARROWCLIFFE TW, RAUT S, SANDS D, HUBBARD AR: Coagulation and chromogenic assays of Factor VIII activity: general aspects, standardization, and recommendations. Semin. Thromb. Hemost. (2002) 28:247-256.
31. LOLLAR P: The Factor VIII assay problem: neither rhyme nor reason. J. Thromb. Haemost. (2003) 1:2275-2279.
32. HUBBARD AR, WELLER LJ, BEVAN SA: A survey of one-stage and chromogenic potencies in therapeutic Factor VIII concentrates. Br. J. Haematol. (2002) 117:247-248.
33. BARROWCLIFFE TW: Standardization of FVIII & FIX assays. Haemophilia (2003) 9:397-402.
34. MIKAELSSON M, OSWALDSSON U, SANDBERG H: Influence of phospholipids on the assessment of Factor VIII activity. Haemophilia (1998) 4:646-650.
35. LEE CA, OWENS D, BRAY G et al.: Pharmacokinetics of recombinant Factor VIII (recombinate) using one-stage clotting and chromogenic Factor VIII assay. Thromb. Haemost. (1999) 82:1644-1647.
36. BOEDEKER BG: Production processes of licensed recombinant Factor VIII preparations. Semin. Thromb. Hemost. (2001) 27:385-394.
37. GRIFFITH M, KINGDON H, LIU SL, BURKART W: In-process controls and characterization of recombinate antihemophilic factor (recombinant). Ann. Hematol (1991) 63:166-171.
38. BRAY GL, GOMPERTS ED, COURTER S et al.: A multicenter study of recombinant Factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood (1994) 83:2428-2435.
39. WHITE GC, COURTER S, BRAY GL, LEE M, GOMPERTS ED: A multicenter study of recombinant Factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb. Haemost. (1997) 77:660-667.
40. INGERSLEV J, CHRISTIANSEN K, RAVN HB, BRAY GL, GOMPERTS ED: Antibodies to heterologous proteins in hemophilia A patients receiving recombinant Factor VIII (Recombinate). Thromb. Haemost. (2002) 87:626-634.
41. ADDIEGO JE, GOMPERTS E, LIU S-L et al.: Treatment of hemophilia A with a highly purified Factor VIII concentrate prepared by anti-fVIIIc immunoaffinity chromatography. Thromb. Haemostas. (1992) 67:19-27.
42. GILES AR, TINLIN S, HOOGENDOORN H et al.: In vivo characterization of recombinant Factor VIII in a canine model of hemophilia A (factor VIII deficiency). Blood (1988) 72:335-339.
43. SCHWARTZ RS, ABILDGAARD CF, ALEDORT LM et al.: Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N. Engl. J. Med. (1990) 323:1800-1805.
44. SEREMETIS S, LUSHER JM, ABILDGAARD CF et al.: Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia (1999) 5:9-16.
45. LUSHER JM, ARKIN S, ABILDGAARD CF, HURST D: Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: update of safety, efficacy and inhibitor development after seven study years. The Kogenate PUP Study Group. Thromb. Haemost. (1997) 162:Abstract PD-664.
46. ROTHSCHILD C, LAURIAN Y, SATRE EP et al.: French previously untreated patients with severe hemophilia A after exposure to recombinant Factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb. Haemost. (1998) 80:779-783.
47. ABSHIRE TC, BRACKMANN HH, SCHARRER I et al.: Sucrose formulated recombinant human antihemophilic Factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb. Haemost. (2000) 83:811-816.
48. ROTHSCHILD C, SCHARRER I, BRACKMANN HH et al.: European data of a clinical trial with a sucrose formulated recombinant Factor VIII in previously treated haemophilia A patients. Haemophilia (2002) 8(Suppl. 2):10-14.
49. GIANGRANDE PL: Safety and efficacy of KOGENATE(R) Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia (2002) 8(Suppl. 2):19-22.
50. SCHARRER I: Experience with KOGENATE(R) Bayer in surgical procedures. Haemophilia (2002) 8(Suppl. 2):15-18.
51. TOOLE JJ, PITTMAN DD, ORR EC et al.: A large region (=95 kDa) of human Factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. USA (1986) 83:5939-5942.
52. PITTMAN DD, ALDERMAN EM, TOMKINSON KN et al.: Biochemical, immunological, and in vivo functional characterization of B-domain-deleted Factor VIII. Blood (1993) 81:2925-2935.
53. SANDBERG H, ALMSTEDT A, BRANDT J et al.: Structural and functional characterization of B-domain deleted recombinant Factor VIII. Semin. Hematol. (2001) 38:4-12.
54. ERIKSSON RK, FENGE C, LINDNER-OLSSON E et al.: The manufacturing process for B-domain deleted recombinant Factor VIII. Semin. Hematol. (2001) 38:24-31.
55. FIJNVANDRAAT K, BERNTORP E, TEN CATE JW et al.: Recombinant, B-domain deleted Factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb. Haemost. (1997) 77:298-302.
56. COURTER SG, BEDROSIAN CL: Clinical evaluation of B-domain deleted recombinant Factor VIII in previously treated patients. Semin. Hematol. (2001) 38:44-51.
57. COURTER SG, BEDROSIAN CL: Clinical evaluation of B-domain deleted recombinant Factor VIII in previously untreated patients. Semin. Hematol. (2001) 38:52-59.
58. LUSHER JM, LEE CA, KESSLER CM, BEDROSIAN CL: The safety and efficacy of B-domain deleted recombinant Factor VIII concentrate in patients with severe haemophilia A. Haemophilia (2003) 9:38-49.
59. HANNA WT, ZIMMERMAN CE: Lack of adequate bleed prevention and FVIII activity recovery with ReFacto: a series of case studies in hemophilia A patients. Blood (2001) 98:531a.
60. GRUPPO RA, BROWN D, WILKES MM, NAVICKIS RJ: Comparative effectiveness of full-length and B-domain deleted Factor VIII for prophylaxis - a meta-analysis. Haemophilia (2003) 9:251-260.
61. INGERSLEV J, OSWALDSSON U, RENLUND S, MIKAELSSON M, THE NORDIC REFACTO STUDY GROUP: Results of a collaborative Nordic field Study (RASPUTIN) on determination of recombinant B-domain deleted Factor VIII in plasma employing a (Refacto) concentrate standard. Thromb. Haemost. (2001) (Suppl.):Abstract.
62. MORFINI M, CINOTTI S, BELLATRECCIA A et al.: A multicenter pharmacokinetic study of the B-domain deleted recombinant Factor VIII concentrate using different assays and standards. J. Thromb. Haemost. (2003) 1:2283-2289.
63. MOUSSALLI M, PIPE SW, HAURI HP et al.: Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII. J. Biol. Chem. (1999) 274:32539-32542.
64. CUNNINGHAM MA, PIPE SW, ZHANG B et al.: LMAN1 is a molecular chaperone for the secretion of coagulation Factor VIII. J. Thromb. Haemost. (2003) 1:2360-2367.
65. EATON DL, WOOD WI, EATON D et al.: Construction and characterization of an active Factor VIII variant lacking the central one-third of the molecule. Biochemistry (Mosc) (1986) 25:8343-8347.
66. LI X, GABRIEL DA: The physical exchange of Factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding. Biochemistry (Mosc) (1997) 36:10760-10767.
67. EWENSTEIN B, COLLINS P., SHAPIRO A. et al.: Global evaluation of ADVATE rAHF-PFM, an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Blood(2003) 102:52a.
68. NEGRIER C, ASTERMARK J, PABINGER I et al.: Surgical evaluation of ADVATE rAHF-PFM, an advanced category recombinant antihemophilic factor prepared using a plasma/albumin-free method. Blood (2003) 102:795a.
69. SAENKO EL, ANANYEVA NM, SHIMA M, HAUSER CAE, PIPE SW: The future of recombinant coagulation factors. J. Thromb. Haemost. (2003) 1:1-8.
70. SWAROOP M, MOUSSALLI M, PIPE SW, KAUFMAN RJ: Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation Factor VIII. J. Biol. Chem. (1997) 272:24121-24124.
71. PITTMAN DD, MARQUETTE KA, KAUFMAN RJ: Role of the B domain for Factor VIII and Factor V expression and function. Blood (1994) 84:4214-4225.
72. PIPE SW, MIAO H, TENDULKAR R, KAUFMAN RJ: Asparagine-linked glycosylation sites within the B domain of coagulation Factor VIII improve secretion efficiency. Blood (2001) 98:705a.
73. MIAO HZ, SIRACHAINAN N, PALMER L et al.: Bioengineering of coagulation Factor VIII for improved secretion. Blood (2004) (In Press).
74. SAENKO EL, YAKHYAEV AV, MIKHAILENKO I, STRICKLAND DK, SARAFANOV AG: Role of the low density lipoprotein-related protein receptor in mediation of Factor VIII catabolism. J. Biol. Chem. (1999) 274:37685-37692.
75. BOVENSCHEN N, HERZ J, GRIMBERGEN JM et al.: Elevated plasma Factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood (2003) 101:3933-3939.
76. SARAFANOV AG, ANANYEVA NM, SHIMA M, SAENKO EL: Cell surface heparan sulfate proteoglycans participate in Factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J. Biol. Chem. (2001) 276:11970-11979.
77. O'MAHONY B: Global haemophilia care: future challenges and opportunities. Haemophilia (2002) 8:515.
78. BURNOUF T, RADOSEVICH M: Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia (2003) 9:24-37.
79. STONEBRAKER JS, AMAND RE, NAGLE AJ: A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community. Haemophilia (2003) 9:245-250.
80. STONEBRAKER JS, AMAND RE, BAUMAN MV, NAGLE AJ, LARSON PJ: Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained Factor VIII demand. Haemophilia (2004) 10:1-9.